STOCK MARKET BSE NSE

Rajasthan govt sends notice to hospital for conducting trials of Patanjali drug on COVID-19 patients

At the Coronil launch, the company had claimed that its medicine can cure the contagious disease within seven days.

Published: 26th June 2020 04:34 PM  |   Last Updated: 26th June 2020 04:34 PM   |  A+A-

Patanjali_ products

Patanjali products. Image used for representation purpose only.

By PTI

JAIPUR: Rajasthan's Health Department has served a notice to NIMS hospital here seeking an explanation on conducting trials of Patanjali Ayurved's drug Coronil on coronavirus patients, an official said on Friday.

"We served notice to the hospital on Wednesday evening seeking explanation in three days. The hospital did not inform the state government nor sought permission," Chief Medical and Health Officer, Jaipur, Dr Narottam Sharma said.

He said the reply from National Institute of Medical Science (NIMS), Jaipur is awaited.

The launch of the drug by yoga guru Ramdev on Tuesday triggered a debate after which the Ayush Ministry sought all information on its trial and put a ban on advertising it as a drug to cure coronavirus.

The Rajasthan government has clarified that the drug cannot be not used as a medicine in the state without the permission of the Ministry of AYUSH.

State Health Minister Raghu Sharma had said on Wednesday that strict action would be taken against the seller as per the rules in case of sale of any drug as a medicine to treat the coronavirus infection.

At the Coronil launch, the company had claimed that its medicine can cure the contagious disease within seven days.

It said Coronil, taken along with another product developed by it, had shown a 100 per cent success rate in clinical trials on infected patients, except those on life support.

Ramdev said the medicines were developed by Patanjali Research Center, Haridwar in association with privately-owned National Institute of Medical Science (NIMS), Jaipur.

The Uttarakhand government will serve a notice to Patanjali Ayurved for launching a drug claiming to be a cure for COVID-19 when it had only applied for a licence to manufacture an immunity booster against cough and fever.

Apart from the notice from the Uttarakhand government, the Haridwar-based firm could also face litigation in Bihar.

A complaint has been filed against it in a Muzaffarpur court over its claim.

A complainant approached the court seeking the registration of an FIR against Ramdev and company chairman Acharya Balkrishna, alleging that they put at risk the lives of lakhs of people by claiming to have developed a COVID-19 cure.

Chief Judicial Magistrate Mukesh Kumar posted the matter for hearing on June 30.

Stay up to date on all the latest Nation news with The New Indian Express App. Download now

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp